| Top Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Investing > Investing - Income Boosting Strategies |
|
Top Articles - Investing - Income Boosting Strategies
Retirees have two major investment goals. They want income to provide for their living expenses today, and they need growth so they can maintain their standard of living in the future. This week I’ll focus on effe According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ctive ways to manage your portfolio that may dramatically increase your income. Next week I’ll share growth-oriented strategies. My clients expect me to find opportunities to increase their income and grow their ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in money. That’s why I’ve developed specific strategies using high-yielding securities--strategies my clients can’t get elsewhere. Understanding the investments used may help you develop your own strategy. High-Divi lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. dend Paying and Preferred Stocks: The days of being able to buy a dominant company like AT&T, hold it for life and live off the dividends are over. A great company today can be a has-been tomorrow. If managed corr here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ctly, though, a basket of high-dividend paying stocks can be a great addition to a senior’s portfolio. There are many quality companies that pay dividends of 6-9% per year. These are often the companies ignored b d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro y Wall Street and other advisors because they have little growth potential. Instead, they have stable cash flows and pay healthy dividends. For instance, Citizens Communications (CZN) is a rural telephone company ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc . Rural doesn’t mean small. They operate in 24 states and are one of the nations’ largest independent telecommunications providers. Boring. Yet it pays out a dividend of over 9%! I’m not saying you should rush out easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi and buy Citizens, but this is just one of many such over-looked companies. Canadian Income Trusts (CITs) are another example of securities that can provide an income stream of 5-8% per year. CITs are foreign sec nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically rities that trade on the Pink Sheets in the U.S. Don’t think that they are risky companies because they trade on the Pink Sheets. They aren’t. In fact, many are some of the largest and most stable businesses in Ca and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ nada. For instance, Yellow Pages Income Fund provides online and offline telephone directories across much of Canada. Its business is stable and doesn’t grow by leaps and bounds, yet it pays a dependable dividend ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi over 5% in U.S. dollars. Moreover, it has steadily increased it. Closed-End Funds (CEF): These are similar to the open-end mutual funds we are all familiar with. The difference is that they act more like a stock ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a . Money is initially raised in a public offering. The money manager then oversees that pool of money. The size of the pool isn’t determined by investors putting money in or taking it out. Just like a stock, invest dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod rs buying and selling shares in the CEF determine its share price, not the underlying value of its investments. This presents opportunity. First, the manager has the ability to buy investments for the long-term. cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin Unlike the open-end fund manager, the CEF manager doesn’t have to sell investments to fund shareholder withdrawals. Secondly, assets can be purchased for a discount to their market value. Morgan Stanley Global Op tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen portunity Bond Fund (MGB) is an example of a closed-end fund that has done well. Its current yield is over 8%. Typically, I only recommend buying CEFs trading at a discount, but this one may be worth its premium. t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel High-yielding investments have up and down cycles so you have to be disciplined and patient. These cycles don’t affect the dividend, but you should only buy when the investment is at or below an established targe ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust price. The problem with these investments is that they require work. They are not investments the average investor should own unless that investor is willing to commit several hours a week to research and monito y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products r each one. You will also have to make adjustments from time to time. On the other hand, isn’t that what people should expect from their advisor? Aren’t you paying them to manage your money? Yet few advisors use . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de these gems. Most advisors don’t even understand these investments nor do they have effective strategies that leverage their benefits. Instead, they focus on selling you, then moving on to the next person. You des elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip erve better. If you aren’t able to invest the time and energy into managing investments like these you should find a professional that will. There’s no reason you should have to settle for low-yielding investments tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:10 Killer Sales Letter Mistakes That Suck Money From Your Business Confessions of an Article Marketer (Part 1) Moving Forward with MLM Lead Generation
|